



ASH 2023

65th ASH Annual Meeting and Exposition

December 9–12, 2023
San Diego, US



TOP ABSTRACTS

To help navigate the exciting content being presented at the 65th ASH Annual Meeting and Exposition, we have provided recommendations for the top abstracts to look out for in lymphoma and CLL.

ASH 2023: Top abstracts in lymphoma and CLL

December 9–12, 2023

Indolent and mantle cell NHL		
Abstract	Title	
106 View	Outcomes of patients with relapsed/refractory mantle cell lymphoma (R/R MCL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-2 and ZUMA-18, an expanded access study	Andre Goy
107 View	Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): a CIBMTR subgroup analysis of high-risk characteristics	Swetha Kambhampati
295 View	Long-term efficacy of a 6-month regimen of rituximab and lenalidomide in follicular lymphoma patients in need of first therapy: updated analysis of the SAKK 35/10 randomized trial	Emanuele Zucca
296 View	Real-world experience of CAR T-cells in patients with relapsed/refractory follicular lymphoma: a Descart Registry analysis from the Lysa	Emmanuel Bachy
297 View	Tazemetostat in combination with R-CHOP in patients with high-risk, frontline follicular lymphoma (Epi-RCHOP): a phase II study from the Lysa	Loic Ysebaert
300 View	Multicenter study of mantle cell lymphoma outcomes following first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy	Yucai Wang
601 View	Clinical outcomes of patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 Elara 3-year follow-up	Stephen J. Schuster
602 View	TRANSCEND FL: Phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma	Franck Morschhauser
603 View	Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and/or refractory follicular lymphoma after ≥ 2 prior therapies: 3-year follow-up from a pivotal phase II study	Stephen J. Schuster
604 View	Subcutaneous (SC) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): first results of a multicenter phase 2 study	Lorenzo Falchi
LBA-2 View	Ibrutinib combined with venetoclax in patients with relapsed/refractory mantle cell lymphoma: primary analysis results from the randomized phase 3 Sympatico study	Michael Wang
605 View	Preliminary findings of a phase Ib/II trial indicate manageable safety and promising efficacy for mosunetuzumab in combination with lenalidomide (m+len) in previously untreated (1L) follicular lymphoma (FL)	Franck Morschhauser

616 View	CD19-targeting CAR T-cell therapy in transformed Waldenström macroglobulinemia/lymphoplasmacytic lymphoma: A Descar-T and US collaborative study	Eric Durot
735 View	A window study of acalabrutinib & rituximab, followed by chemotherapy & autograft (ASCT) in fit patients with treatment naïve mantle cell lymphoma (MCL): first report of the investigator-initiated Australasian Leukaemia & Lymphoma Group NHL33 'Wamm' trial	Eliza A. Hawkes
738 View	A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma	Anita Kumar
979 View	Induction and maintenance therapy in elderly patients with mantle cell lymphoma: Double-randomized MCL R2 elderly clinical trial by the European Mantle Cell Lymphoma Network	Vincent Ribrag
981 View	Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study	Jonathon B. Cohen
3024 View	Safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with relapsed/refractory mantle cell lymphoma (r/r MCL): updated results from a phase II open-label study in China	Yuqin Song
3035 View	Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma: updated phase 1b results of Symphony-1 with 22.5 months follow-up	Gilles Salles
3039 View	Orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study: long term follow-up results	Xinxin Cao
3055 View	Marsun, a phase III, multicenter, open label, randomized, controlled study investigating mosunetuzumab-lenalidomide versus investigator choices in patients with relapsed or refractory marginal zone lymphoma (R/R MZL)	Catherine Thieblemont

Hodgkin's lymphoma		
Abstract	Title	
181 View	Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged ≥ 60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826	Sarah C. Rutherford
182 View	PD-1 blockade before autologous stem cell transplantation improves outcomes in relapsed/refractory classic Hodgkin lymphoma: results from a multicenter cohort	Sanjal H. Desai
382 View	Treatment patterns and outcomes for patients with classic Hodgkin lymphoma (cHL) and cardiomyopathy with low ejection fraction (EF): real-world evidence (RWE) from 16 US academic centers	Kaitlin Annunzio
607 View	Results from an intergroup randomized phase II study of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed/refractory classic Hodgkin lymphoma: a trial of the ECOG-ACRIN Research Group (E4412)	Catherine S. Diefenbac
608 View	Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced stage classical Hodgkin lymphoma: efficacy and safety results from the single arm phase 2 study	Hun Ju Lee
609 View	IMM01 plus tislelizumab in prior anti-PD-1 failed classic Hodgkin lymphoma: An open label, multicenter, phase 2 study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity	Keshu Zhou
610 View	Progression-free survival (PFS) and toxicity with nivolumab-AVD compared to brentuximab vedotin-AVD in pediatric advanced stage (AS) classic Hodgkin lymphoma (cHL), results of SWOG S1826	Kara M. Kelly
1700 View	Pembrolizumab (pembro) in children and young adults with low-risk classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo): early results from the phase 2 keynote-667 study	Lisa Giulino Roth

T-cell lymphoma		
Abstract	Title	
186 View	Epidemiology, clinical features and outcomes of peripheral T-cell lymphoma in Latin America	Thais Fischer
302 View	Efficacy and safety of valemestostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: primary results of the phase 2 VALENTINE-PTCL01 study	Steven M. Horwitz
305 View	Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: full analysis of the multinational pivotal study results (JACKPOT8)	Yuqin Song

Aggressive B-cell non-Hodgkin lymphoma

Abstract	Title	
68 View	Treatment intensity and outcomes in elderly patients with DLBCL receiving first line therapy	Steven M. Bair
70 View	Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: a prospective geriatric assessment (GA) study	Pallawi Torka
103 View	Real-world evidence in the United States (US) of the impact of bridging therapy prior to axicabtagene ciloleucel (axi-cel) for the treatment of relapsed or refractory large B-cell lymphoma (R/R LBCL)	Michael Roderick Cook
105 View	Lisocabtagene maraleucel as second-line therapy for R/R large B-cell lymphoma in patients not intended for hematopoietic stem cell transplant: final analysis of the phase 2 PILOT study	Alison R. Sehgal
169 View	Plasma circulating tumor dNA (ctDNA) as an alternative to tissue DNA for genotyping of DLBCL: results from the POLARIX study	Fabrice Jardin
225 View	Circulating tumor DNA dynamics as early outcome predictors for lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma from the phase 3 TRANSFORM study	Ash A. Alizadeh
228 View	Efficacy of chimeric antigen receptor T-cell therapy is not impaired by previous bispecific antibody treatment in patients with large B-cell lymphoma	Gloria Iacoboni
231 View	Results of the Astral study: A prospective phase II clinical study of the German Lymphoma Alliance to assess the efficacy and toxicity of high-dose chemotherapy followed by allogeneic stem cell transplantation as treatment of primary progressive and relapsed aggressive non-Hodgkin lymphoma	Bertram Glass
311 View	Chimeric antigen receptor T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma: a multicenter study	Aung M. Tun
427 View	Circulating tumor DNA analysis associates with progression-free survival (PFS) with odronextamab monotherapy in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL): Identification of minimal residual disease status and high-risk subgroups from the phase 2 ELM-2 study	Jon E. Arnason
433 View	Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume	Martin Hutchings
436 View	Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)	Sabarish Ayyappan

437 View	Ibrutinib added to standard conditioning and as consolidation therapy following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell subtype diffuse large B-cell lymphoma (ABC-DLBCL): Primary analysis of the US Intergroup double-blind randomized phase III study alliance A051301/BMT-CTN 1201	Charalambos Andreadis
613 View	Mosunetuzumab plus polatuzumab vedotin demonstrates a favorable safety profile and efficacy in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): primary analysis of a phase Ib/II study	Elizabeth Lihua Budde
781 View	Autologous transplant (auto-HCT) is associated with improved clinical outcomes compared to CAR-T therapy in patients (pts) with large B-cell lymphoma (LBCL) achieving a complete remission	Mazyar Shadman
853 View	Results of the phase II of Epirchop study, evaluating the efficacy of tazemetostat in combination with R-CHOP in elderly newly diagnosed diffuse large B cell lymphoma (DLBCL): a Lysa study	Clementine Sarkozy
855 View	Mosunetuzumab and polatuzumab vedotin demonstrates preliminary efficacy in elderly unfit/frail patients with previously untreated diffuse large B-cell lymphoma	Adam J. Olszewski
893 View	Glofitamab monotherapy in patients with non-Hodgkin B-cell lymphoma after failing CAR T-cell infusion: primary analysis of the Bicar study, a phase II Lysa study	Pierre Sesques
894 View	3-year analysis of ZUMA-12: A phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL)	Julio C. Chavez
1031 View	Efficacy of CD19-directed CAR T cell therapy in patients with primary or secondary CNS lymphoma – an analysis of the EBMT Lymphoma WP and the Gocart Coalition	Anna Ossami Saidy
1032 View	Five year outcomes of patients with large B-cell lymphoma treated with standard-of-care axicabtagene ciloleucel: results from the US Lymphoma CAR-T Cell Consortium	Jay Y. Spiegel
2987 View	Early prediction of treatment response by circulating tumor DNA profiling in patients with diffuse large B-cell lymphoma receiving CAR T-cell therapy	Anna Katharina Foerster
3000 View	Deciphering the clinical benefit of Pola-R-CHP versus R-CHOP in different genetic subtypes beyond cell of origin in the POLARIX study	Franck Morschhauser
5146 View	Comprehensive geriatric assessment and geriatric intervention in older patients with newly diagnosed lymphoma: a prospective study	Alberto Lopez Garcia

Chronic lymphocytic leukemia

Abstract	Title	
202 View	Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma	Jennifer R. Brown
269 View	Impact of ibrutinib dose reduction on duration of therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma	Mazyar Shadman
325 View	Pirtobrutinib in post-cBTKi CLL/SLL: ~30 months follow-up and subgroup analysis with/without prior BCL2i from the phase 1/2 BRUIN study	Jennifer A. Woyach
330 View	Lisocabtagene maraleucel (liso-cel) in R/R CLL/SLL: 24-month median follow-up of TRANSCEND CLL 004	Tanya Siddiqi
497 View	Outcomes of patients with Richter transformation without prior chemoimmunotherapy for CLL/SLL: an international multicenter retrospective study	Adam S. Kittai
631 View	Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: report of the phase III UK NCRI FLAIR study	Peter Hillmen
633 View	Relapse after first-line fixed duration ibrutinib + venetoclax: high response rates to ibrutinib retreatment and absence of BTK mutations in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with up to 5 years of follow-up in the phase 2 Captivate study	Paolo Ghia
635 View	First-line venetoclax combinations in fit patients with CLL: 4-year follow-up and NGS-based MRD analysis from the phase 3 GAIA/CLL13 trial	Moritz Fürstenau
636 View	Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: 6-year follow-up of Elevate-TN	Jeff P. Sharman
3267 View	Ibrutinib, fludarabine, cyclophosphamide and obinutuzumab (iFCG) for firstline treatment of patients with CLL with mutated IGHV and without del(17p)/TP53 mutation: Six-year follow-up analyses	Nitin Jain
3283 View	Impact of COVID-19 in patients with chronic lymphocytic leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre Seifem study	Francesco Autore

Advances in disease biology

Abstract	Title	
1892 View	An unsupervised machine learning method stratifies chronic lymphocytic leukemia patients into novel categories with different risk of early treatment	Federico Pozzo



ASH 2023

Follow us on X to keep up to date
with the latest from the congress

@lymphomahub

#ASH23

View all @lymphomahub tweets from #ASH23



Brought to you by

